Europe In-Vitro Diagnostics (IVD) Market Report by Test Types, Product, Application, Technology, End User, Countries and Companies Analysis 2026-2034

Europe In-Vitro Diagnostics Market Size & Forecast

Europe In-Vitro Diagnostics (IVD) Market is projected to grow from US$ 26.54 Billion in 2025 to US$ 43.75 Billion by 2034, expanding at a CAGR of 5.71% during 2026–2034. Market growth is being driven by the rising demand for early and accurate disease detection, increasing adoption of personalized medicine, and continued advancements in diagnostic technologies. In addition, Europe’s aging population and growing prevalence of chronic diseases are creating sustained demand for clinical diagnostic testing. Rapid developments in molecular diagnostics, immunoassays, genetic testing, and point-of-care diagnostics are further enhancing testing capabilities and accessibility.

What is In-Vitro Diagnostics and its Uses & Popularity in Europe

In-Vitro Diagnostics (IVD) refers to medical tests performed outside the human body using biological samples such as blood, urine, saliva, tissue, and other specimens to detect, diagnose, monitor, or predict diseases. IVD includes molecular diagnostics, immunoassays, clinical chemistry, hematology, microbiology, genetic testing, and point-of-care testing. These technologies support the detection and management of infectious diseases, cancer, diabetes, cardiovascular disorders, genetic conditions, and other chronic illnesses.

In Europe, IVD is widely used in hospitals, clinical laboratories, physician offices, blood banks, pharmacies, and increasingly at home. Around two-thirds of clinical decisions are estimated to rely on information provided by IVDs, highlighting its importance to healthcare delivery. Europe’s aging population further strengthens demand: people aged 65 and above represented 21.6% of the EU population in 2024, compared with 16.4% in 2004. Advances in molecular testing, automation, personalized medicine, and decentralized diagnostics are also increasing the adoption and clinical importance of IVD across European healthcare systems.

European Countries by Chronic Disease Cases in 2025

• Germany – 52 Million+
  Germany ranks first, supported by its large population, aging demographic structure, and substantial burden of cardiovascular disease, diabetes, cancer, and other long-term conditions. OECD data report diabetes prevalence of 6.6% among adults.
• United Kingdom – 41 Million+
  The UK has a substantial chronic disease burden associated with cardiovascular conditions, diabetes, respiratory diseases, obesity-related disorders, and an aging population. OECD data report an adult diabetes prevalence of 8.8%.
• France – 39 Million+
  France has a significant chronic disease population despite comparatively favorable outcomes for several conditions. Its aging population contributes to continued demand for long-term disease management and diagnostic services. OECD reports 2.7% adult diabetes prevalence.
• Italy – 35 Million+
  Italy’s older population contributes significantly to the prevalence of chronic and age-related diseases. Diabetes prevalence among Italian adults is estimated at 7.2%, while chronic disease management remains an important healthcare priority.
• Spain – 24 Million+
  Spain has a growing chronic disease burden linked to population aging, cardiovascular conditions, diabetes, cancer, and other non-communicable diseases. OECD data indicate adult diabetes prevalence of 3.6%.
• Poland – 18 Million+
  Poland’s chronic disease burden reflects demographic aging and the prevalence of cardiovascular, metabolic, respiratory, and other long-term conditions. Adult diabetes prevalence was approximately 10.8% in OECD data.
• Netherlands – 11 Million+
  The Netherlands faces substantial demand for chronic disease prevention and management, including diabetes, cardiovascular disease, and age-related conditions. OECD data report a 6.4% adult diabetes prevalence.
• Romania – 10 Million+
  Romania has a considerable chronic disease burden associated with cardiovascular diseases, metabolic disorders, cancer, and population aging. Chronic disease prevention and improved access to healthcare remain important priorities.
• Belgium – 7 Million+
  Belgium has a significant population living with long-term health conditions, supported by its aging population and prevalence of cardiovascular and metabolic diseases. OECD data report 6.7% adult diabetes prevalence.
• Sweden – 6 Million+
  Sweden’s chronic disease burden is shaped by population aging and long-term conditions requiring continuous monitoring and treatment. OECD data report 5.1% adult diabetes prevalence, while chronic-care demand remains important within its well-developed healthcare system.

Source basis: European Commission Country Health Profiles 2025

Growth Drivers of the Europe In-Vitro Diagnostics Market

Aging Population and Rising Chronic Disease Burden

Europe’s rapidly aging population is creating sustained demand for diagnostic testing, particularly for diseases associated with older age. According to Eurostat, the proportion of people aged 65 and over reached 21.6% of the EU population in 2024, increasing from 16.4% in 2004. The share of people aged 80 and above also increased from 3.8% to 6.1% over the same period. Older populations typically require more frequent monitoring for diabetes, cardiovascular disease, cancer, kidney disorders, and other chronic conditions, increasing demand for blood tests, clinical chemistry, immunoassays, and molecular diagnostics. Industry estimates also indicate that more than 50 million people in Europe live with multiple chronic diseases, reinforcing the need for continuous disease monitoring and early detection. As European healthcare systems increasingly emphasize prevention, early diagnosis, and management outside hospitals, IVD testing is becoming an essential component of routine healthcare. The combination of demographic aging, multimorbidity, and increased screening is therefore supporting long-term market expansion.

Rising Adoption of Molecular Diagnostics and Personalized Medicine

Technological advancement in molecular diagnostics, genetic testing, companion diagnostics, and precision medicine is significantly expanding the European IVD market. Molecular platforms can identify pathogens, genetic mutations, biomarkers, and disease characteristics with increasing speed and accuracy, supporting earlier diagnosis and more targeted treatment decisions. The expansion of oncology is particularly important because biomarker testing is increasingly used to determine whether patients are suitable for specific targeted therapies. Industry estimates identify precision medicine and companion diagnostics as important contributors to European IVD demand.  At the same time, point-of-care and decentralized testing are bringing diagnostic capabilities closer to patients in primary-care facilities, pharmacies, emergency departments, and home settings. The European Commission recognizes IVD applications ranging from pregnancy and COVID-19 tests to cancer genetic testing and high-throughput infectious-disease screening. Continued investment in automation, artificial intelligence, multiplex testing, and digital laboratory systems is expected to further improve turnaround times and strengthen adoption of advanced IVD technologies across Europe.

Strong Healthcare Infrastructure and Regulatory Focus on Diagnostic Quality

Europe’s established healthcare infrastructure and increasingly stringent regulatory framework are supporting demand for reliable, high-quality diagnostic technologies. The EU In-Vitro Diagnostic Regulation (IVDR), Regulation 2017/746, has applied since May 26, 2022, introducing a risk-based classification system, stronger performance evaluation requirements, greater involvement of notified bodies, improved transparency, and enhanced post-market surveillance. Although compliance increases requirements for manufacturers, it also encourages investment in product quality, clinical evidence, laboratory performance, and safety. The European Commission has extended transition periods for certain legacy IVDs to facilitate a staged move to the new framework; higher-risk devices have different transition deadlines from lower-risk products. In parallel, European hospitals and laboratories are investing in automated analyzers, integrated laboratory information systems, high-throughput platforms, and decentralized testing. These developments create opportunities for established IVD manufacturers as well as innovative companies developing next-generation diagnostic platforms, reagents, software, and testing services.

Challenges of the Europe In-Vitro Diagnostics Market

Complex Regulatory Requirements and Compliance Costs

One of the major challenges facing the European IVD market is the complexity of regulatory compliance under the IVDR. The regulation introduced more stringent requirements for clinical evidence, performance evaluation, quality management, conformity assessment, and post-market surveillance. For manufacturers, particularly smaller companies, these requirements can increase the cost and time required to bring new diagnostic products to market. The European Commission has therefore implemented staggered transition periods for eligible legacy devices, with deadlines varying according to device classification. Manufacturers must also establish appropriate quality-management systems and, where applicable, work with notified bodies for conformity assessment. These requirements can create resource constraints, particularly for companies with extensive product portfolios. Delays in certification may also affect product availability and innovation cycles. While the regulatory framework is designed to improve safety and reliability, compliance costs and administrative complexity can temporarily constrain market growth, especially among smaller European IVD developers and companies introducing innovative or highly specialized diagnostic technologies.

High Costs, Reimbursement Pressure and Unequal Access to Advanced Diagnostics

European IVD market also faces challenges related to healthcare budgets, reimbursement policies, and differences in diagnostic access between countries. Advanced molecular tests, genomic assays, companion diagnostics, automated laboratory systems, and sophisticated point-of-care platforms can require substantial investments in equipment, consumables, personnel, and infrastructure. Healthcare providers must therefore balance the clinical benefits of innovative testing against cost-effectiveness and available reimbursement. Europe is not a single healthcare market; national healthcare systems differ considerably in procurement procedures, reimbursement structures, laboratory capacity, and adoption of new technologies. This can result in uneven availability of advanced IVD testing across countries and regions. Furthermore, laboratories need skilled professionals capable of operating increasingly sophisticated molecular and automated platforms. The European Commission notes that the IVDR has increased requirements for performance evaluation, conformity assessment, and post-market surveillance, adding to manufacturers’ and healthcare organizations’ compliance responsibilities. Consequently, controlling diagnostic costs while ensuring equitable access, maintaining laboratory capacity, and adopting innovative technologies remains an important challenge for sustained European IVD market development.

Major IVD Product Launches and Developments in Europe

• bioMérieux SA – Expanded its BIOFIRE infectious-disease diagnostic portfolio in 2025, strengthening rapid molecular testing solutions for respiratory and other infectious diseases across European healthcare settings.
• QIAGEN – Expanded its QIAstat-Dx syndromic testing portfolio under the EU IVDR framework, including solutions for rapid identification of multiple pathogens from a single patient sample.
• Roche Diagnostics – Continued expanding its LumiraDx point-of-care diagnostic technology in European markets, supporting decentralized testing and faster access to diagnostic results.
• Siemens Healthineers – Advanced its European diagnostic portfolio through AI-enabled laboratory and digital pathology solutions, helping hospitals improve workflow efficiency, image analysis, and diagnostic decision-making.
• Inbiome – Advanced rapid bacterial identification technology designed to support faster pathogen identification and antimicrobial-treatment decisions in European clinical settings.
• QIAGEN – Continued development of QIAcube, QIAsymphony, and QIAstat-Dx solutions, strengthening laboratory automation, sample preparation, and molecular diagnostic workflows.
• bioMérieux SA – Expanded deployment of the BIOFIRE SPOTFIRE system, supporting decentralized multiplex molecular testing and rapid respiratory pathogen detection.
• Roche Diagnostics – Strengthened its cobas molecular diagnostics portfolio and near-patient testing capabilities, addressing demand for automated and high-throughput diagnostic solutions.
• Siemens Healthineers – Expanded its Atellica laboratory diagnostics ecosystem, including immunoassay and clinical chemistry automation designed to improve laboratory productivity and testing capacity.
• Numares Health AG – Continued development and expansion of its AXINON® automated IVD platform, applying metabolomics-based diagnostics to areas including chronic disease and cancer detection.

Growing Adoption of High-Sensitivity Immunoassays

ELISA (Enzyme-Linked Immunosorbent Assay) and CLIA (Chemiluminescence Immunoassay) segments are important components of Europe’s IVD market, supporting hormone testing, infectious-disease screening, autoimmune diagnostics, oncology biomarkers, HIV, hepatitis, and other clinical applications. Immunoassay was the largest IVD technology segment in Europe in 2025, reflecting its extensive use in routine screening and chronic-disease monitoring. Automation is further improving laboratory productivity by enabling high-throughput testing, standardized workflows, and reduced manual intervention. CLIA platforms are particularly attractive for laboratories requiring rapid and sensitive automated testing, while ELISA remains widely used across clinical, research, and diagnostic settings. The growing prevalence of chronic and infectious diseases, combined with Europe’s established laboratory infrastructure, continues to support demand. Increasing adoption of automated analyzers, multiplex testing, and biomarker-based diagnostics is also expanding applications. As healthcare systems emphasize early detection and personalized treatment, ELISA and CLIA technologies are expected to remain essential elements of European immunodiagnostics.

Expansion of Decentralized and Near-Patient Testing

Rapid tests are becoming increasingly important in Europe because they provide quick diagnostic results and can be performed in hospitals, physician offices, pharmacies, community settings, and homes. Applications include infectious diseases, pregnancy, glucose monitoring, respiratory infections, and other screening needs. Disposable IVD devices represented a substantial share of the European market in 2025, reflecting continued demand for convenient single-use testing formats.  Point-of-care and home-care testing are also expanding as healthcare systems seek to reduce laboratory workloads and improve access to diagnosis. The COVID-19 pandemic significantly increased public familiarity with rapid antigen testing and demonstrated the value of decentralized diagnostics during infectious-disease outbreaks. Current innovation is moving toward multiplex rapid tests, connected devices, and platforms capable of delivering laboratory-quality information closer to patients.

Automation and High-Throughput Laboratory Modernization

European IVD instruments market is expanding as hospitals, diagnostic laboratories, and research institutions invest in automated and high-throughput analyzers. Major equipment categories include clinical chemistry analyzers, hematology systems, immunoanalyzers, molecular diagnostic platforms, and point-of-care instruments. Instruments accounted for approximately 32% of the European IVD market by product in 2025 in one recent market assessment, while reagents and kits represented 68%, demonstrating the continuing importance of installed analyzer fleets. Laboratories are increasingly integrating robotics, laboratory information systems, middleware, artificial intelligence, and automated sample handling to improve throughput and reduce manual errors. Replacement of aging equipment and demand for scalable systems are also supporting instrument procurement. Growing testing volumes associated with chronic diseases, oncology, infectious diseases, and personalized medicine should continue encouraging healthcare providers to modernize laboratory infrastructure.

Increasing Demand for Rapid Pathogen Detection

Infectious diseases remain a major application area for European IVD because timely diagnosis supports treatment selection, infection control, surveillance, and outbreak management. The European market includes tests for influenza, HIV, hepatitis, tuberculosis, COVID-19, respiratory infections, and other pathogens, using molecular, antigen, immunoassay, and microbiology technologies. Molecular diagnostics and multiplex respiratory panels are increasingly valuable because they can identify multiple pathogens from a single specimen and support faster clinical decisions. Growing international mobility, antimicrobial resistance, seasonal respiratory infections, and preparedness for future outbreaks are sustaining diagnostic demand. European laboratories are also adopting automated and integrated platforms to increase testing capacity. Continued investment in surveillance and early detection, together with demand for decentralized testing, is expected to maintain the infectious-disease segment as a major contributor to Europe’s IVD industry.

Routine Testing and Chronic Disease Management

Clinical chemistry represents one of the largest components of Europe’s IVD market and is essential for routine assessment of metabolic, renal, hepatic, and cardiovascular health. Common tests include blood glucose, electrolytes, liver enzymes, kidney-function markers, lipids, and other biochemical parameters. High testing volumes are supported by the increasing prevalence of diabetes, cardiovascular conditions, kidney disorders, and other chronic diseases requiring regular monitoring. Automated chemistry analyzers allow laboratories to process large numbers of samples with improved consistency and turnaround times. Modern platforms increasingly incorporate sample automation, integrated workflows, digital connectivity, and advanced quality-control systems. The continued expansion of centralized laboratories and hospital networks is supporting demand for high-throughput systems. Furthermore, Europe’s aging population is increasing the need for routine screening and disease monitoring. These factors are expected to sustain clinical chemistry as a core revenue-generating segment within the European IVD market.

Centralized Testing and Digital Laboratory Transformation

Diagnostic laboratories form the backbone of Europe’s IVD ecosystem by processing large volumes of tests across clinical chemistry, hematology, molecular diagnostics, immunology, microbiology, and other specialties. Laboratories are increasingly consolidating and adopting centralized, high-throughput facilities to achieve economies of scale while maintaining testing quality. Automation, laboratory information systems, artificial intelligence, robotics, and digital connectivity are helping laboratories manage growing workloads and improve turnaround times. Germany illustrates the scale of this infrastructure: around 108,000 people work in medical laboratories, while laboratory diagnostics costs approximately €12.9 billion annually. Partnerships among diagnostic companies, biotechnology firms, universities, and healthcare providers are also encouraging innovation. Increasing demand for molecular testing, infectious-disease screening, oncology biomarkers, and precision medicine should continue to support laboratory expansion and modernization throughout Europe.

Strong Laboratory Infrastructure and Diagnostic Innovation in Germany

Germany represents one of Europe’s most important IVD markets, supported by advanced healthcare infrastructure, extensive laboratory networks, medical research capabilities, and strong demand for diagnostic technologies. Germany’s laboratory ecosystem is extensive: approximately 108,000 people work in medical laboratories, and annual laboratory diagnostics expenditure is estimated at €12.9 billion, equivalent to about 2.6% of total healthcare expenditure. Around 1,200 specialists in laboratory medicine and 840 specialists in microbiology support diagnostic services nationwide. Demand is strengthened by population aging, chronic diseases, oncology testing, infectious-disease diagnostics, and personalized medicine. Automation and digitalization are also transforming laboratories, with large diagnostic units increasingly supported by sophisticated logistics and data infrastructure. Germany’s strong research environment and established diagnostic industry provide additional opportunities for molecular diagnostics, immunoassays, clinical chemistry, and next-generation IVD platforms.

Preventive Healthcare and Advanced Molecular Diagnostics in France

France has a well-developed IVD market supported by its established healthcare system, laboratory infrastructure, national screening activities, and emphasis on disease prevention and early diagnosis. Demand is supported by testing for infectious diseases, oncology, chronic conditions, and other disorders requiring continuous monitoring. Molecular diagnostics is becoming increasingly important as healthcare providers adopt genetic testing, biomarker analysis, and companion diagnostics to support personalized treatment decisions. France also has a strong scientific and biotechnology ecosystem, including major research institutions and diagnostic companies, which contributes to innovation. Laboratories are increasingly investing in automation, integrated analyzers, digital systems, and high-throughput testing capabilities to improve efficiency. The country’s aging population further supports routine diagnostic testing, particularly for cardiovascular, metabolic, and cancer-related conditions. Continued investment in laboratory modernization, precision medicine, and preventive healthcare is expected to sustain France’s position as a significant European IVD market.

NHS Demand and Growth of Decentralized Diagnostics in the United Kingdom

United Kingdom is an important European IVD market, supported by the NHS, advanced clinical laboratories, biotechnology research, and strong adoption of diagnostic innovation. Demand is being driven by infectious-disease testing, oncology diagnostics, chronic disease monitoring, genetic testing, and personalized medicine. Point-of-care and home-based diagnostics have gained greater importance as healthcare providers seek to deliver testing closer to patients and reduce pressure on centralized facilities. Molecular diagnostics and companion diagnostics are also benefiting from advances in genomics and precision medicine. At the same time, the UK’s separate regulatory environment creates additional considerations for IVD manufacturers operating after Brexit. Manufacturers must manage UK-specific regulatory requirements alongside European market requirements when selling across both markets. Despite these complexities, the UK’s research capabilities, healthcare infrastructure, and innovation ecosystem provide strong foundations for continued IVD market development.

Digital Healthcare and Advanced Laboratory Automation

Netherlands has a technologically advanced IVD environment supported by an efficient healthcare system, strong laboratory infrastructure, digital-health adoption, and collaboration among universities, biotechnology companies, and diagnostic manufacturers. Demand is increasing for molecular diagnostics, clinical chemistry, immunodiagnostics, rapid testing, and point-of-care solutions. The Netherlands is also identified as a market where genotype-guided drug dosing and precision-medicine applications are progressing, creating opportunities for advanced molecular and companion diagnostics. Laboratories are increasingly adopting automated, high-throughput systems to manage testing volumes while improving consistency and turnaround times. Digital connectivity between diagnostic instruments, laboratory information systems, clinicians, and patients is further supporting modernization. Home-based and decentralized testing are gaining attention as healthcare systems seek convenient approaches to monitoring and early detection. Collaboration between academic institutions and the diagnostics industry strengthens research and commercialization of new technologies. With continued investment in digital healthcare, precision medicine, automation, and patient-centered diagnostics, the Netherlands is positioned as an important innovation-oriented market within Europe’s broader IVD industry.

Europe In-Vitro Diagnostics (IVD) Market Segments

Test Types

• ELISA & CLIA
• PCR
• Rapid Test
• Fluorescence Immunoassays (FIA)
• In Situ Hybridization
• Transcription Mediated Amplification
• Sequencing
• Colorimetric Immunoassay
• Radioimmunoassay (RIA)
• Isothermal Nucleic Acid Amplification Technology
• Others

Product

• Services
• Instruments
• Reagents

Application

• Infectious Disease
• Diabetes
• Cardiology
• Oncology
• Nephrology
• Autoimmune Diseases
• Drug Testing
• Other Applications

Technology

• Immunoassay
• Clinical Chemistry
• Molecular Diagnostics/Genetics
• Hematology
• Microbiology
• Coagulation
• Others

End User

• Hospitals
• Laboratories
• Home Care
• Others

Countries

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Russia
• Poland
• Greece
• Norway
• Romania
• Portugal
• Rest of Europe

Companies have been covered from 5 viewpoints

• Overviews
• Key Person
• Recent Developments
• Product Portfolio    
• Revenue

Company Analysis

• Roche Diagnostics
• Abbott Diagnostics
• Siemens Healthineers
• Danaher Corporation
• Thermo Fisher Scientific
• Sysmex Corporation

Report Details: